Channel 8’s Daytime aired nationally an interview with two senior executives of Titan Pharmaceuticals (NASDAQ:TTNP) – Dane Hallberg, EVP and chief commercial officer, and Dr. Kate DeVarney, EVP and chief scientific officer – about the opioid crisis in America, which is killing 100 people a day, and the company’s six-month Probuphine implant of the drug, buprenorphine, to treat opioid use disorder and addiction.
Dr. DeVarney said Probuphine is a “game changer” because it takes away a patient’s withdrawal symptoms and cravings. Studies have shown that the longer a patient can stay in treatment, the better the outcome. “Keeping a patient in a continuous state of treatment for six months, lowers the risk of relapse and overdose, and is a benefit,” she added.
Mr. Hallberg said Probuphine is readily available through the company’s specialty pharmacy partners and trained physicians, and is widely reimbursed by insurance companies.
